The shares of Senores Prescription drugs Restricted had been buying and selling at ₹570.70 up by ₹36.90 or 6.91 per cent on the NSE at present at 2.32 pm.
Senores Prescription drugs Restricted introduced the acquisition of US advertising and marketing rights for Roflumilast tablets by way of its American subsidiary. The cope with Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Worldwide, contains the USFDA-approved Abbreviated New Drug Software (ANDA) for 250 mcg and 500 mcg tablets.
Roflumilast is used to cut back COPD exacerbations in sufferers with extreme persistent bronchitis. The US marketplace for the drug was valued at roughly $32 million as of June 2024, in response to IQVIA knowledge, and $46 million as of September 2024, per Symphony.
- Additionally learn: MRO-TEK Realty rebrands as Umiya Buildcon Restricted
The Ahmedabad-based firm plans to fabricate the drug at its US facility and can fund the acquisition utilizing proceeds from its current IPO. Managing Director Swapnil Shah mentioned the acquisition aligns with the corporate’s technique to enter area of interest, under-penetrated generic formulations.
Senores at present has 24 ANDAs and 21 CMO/CDMO industrial merchandise accredited for US distribution. The corporate operates two formulation manufacturing services – an FDA-approved plant in Atlanta, USA, and a WHO-GMP accredited facility in Chhatral, India. It additionally maintains two API manufacturing services close to Ahmedabad and three R&D websites throughout India and the USA.
